4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	275.59	249.11	52.35	153	276.73	49.65
Short-Term Investments	250.32	39.12	161.2	94.78	0	0
Cash & Cash Equivalents	525.91	288.23	213.55	247.78	276.73	49.65
Cash Growth	162.36%	34.97%	-13.81%	-10.46%	457.33%	-45.89%
Receivables	0	0	0	0.05	1.49	0.98
Other Current Assets	9.68	8.36	6.96	8.46	4.44	1.88
Total Current Assets	535.59	296.59	220.51	256.28	282.66	52.51
Property, Plant & Equipment	30.58	31.67	35.35	28.95	5.07	5.05
Long-Term Investments	62.94	10.95	4.91	67.65	0	0
Other Long-Term Assets	0.77	0.68	1.08	0.6	0.6	0.68
Total Long-Term Assets	94.3	43.3	41.34	97.21	5.68	5.73
Total Assets	629.88	339.89	261.85	353.49	288.33	58.23
Accounts Payable	4.22	3.52	3.32	4.76	1.79	1.74
Deferred Revenue	1.32	1.25	1.96	5.09	19.81	19.47
Current Debt	3.17	3.15	2.66	1.23	0	0
Other Current Liabilities	7.69	11.04	7.79	5.25	-4.86	-8.26
Total Current Liabilities	16.4	18.95	15.73	16.34	16.74	12.96
Long-Term Debt	11	11.52	13.47	15.22	0	0
Other Long-Term Liabilities	1.92	1.59	1.31	2.83	15.2	15.27
Total Long-Term Liabilities	12.92	13.11	14.78	18.04	15.2	15.27
Total Liabilities	29.32	32.06	30.51	34.38	31.94	28.22
Total Debt	14.17	14.67	16.12	16.45	0	0
Debt Growth	-9.64%	-9.01%	-1.97%	-	-	-
Retained Earnings	-447.73	-415.33	-314.49	-207	-135.68	-79.03
Comprehensive Income	-0.11	0.02	-1.2	-0.42	0	0
Shareholders' Equity	600.56	307.83	231.34	319.11	256.39	-72.97
Net Cash / Debt	511.74	273.56	197.43	231.33	276.73	49.65
Net Cash / Debt Growth	176.96%	38.56%	-14.65%	-16.41%	457.33%	-45.89%
Net Cash Per Share	10.39	6.99	6.10	8.34	43.03	9.66
Working Capital	519.19	277.64	204.78	239.94	265.91	39.55
Book Value Per Share	12.19	7.87	7.15	11.51	39.87	-14.19

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).